Global Blood Therapeutics (DB:G5B) - Prezzo delle azioni, notizie e analisi

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

G5B Panoramica delle azioni

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD).

Informazioni sull'azienda

G5B analisi fondamentale
Punteggio fiocco di neve
Valutazione	3/6
Crescita futura	5/6
Prestazioni passate	0/6
Salute finanziaria	2/6
Dividendi	0/6

Premi

Trading at 68.4% below our estimate of its fair value

Earnings are forecast to grow 66.18% per year

Analisi del rischio

Highly volatile share price over the past 3 months

Shareholders have been diluted in the past year

Significant insider selling over the past 3 months

Global Blood Therapeutics, Inc. Concorrenti

Biotest

XTRA:BIO3

€1.3b

Formycon

XTRA:FYB

€937.6m

MorphoSys

XTRA:MOR

€2.5b

Heidelberg Pharma

XTRA:HPHA

€112.3m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Global Blood Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$68.40
Massimo di 52 settimane	US$70.48
Minimo di 52 settimane	US$20.83
Beta	0.46
1Variazione di 1 mese	2.18%
Variazione a 3 mesi	110.88%
Variazione di 1 anno	212.76%
3Variazione a 3 anni	62.86%
Variazione a 5 anni	144.90%
Variazione dall'IPO	48.47%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	G5B	DE Biotechs	DE Mercato
7D	-1.5%	2.6%	4.5%
1Y	212.8%	-16.4%	13.4%

Ritorno vs Industria: G5B exceeded the German Biotechs industry which returned -9.2% over the past year.

Rendimento vs Mercato: G5B exceeded the German Market which returned -24.5% over the past year.

Volatilità dei prezzi

Is G5B's price volatile compared to industry and market?
G5B volatility
G5B Average Weekly Movement	17.1%
Biotechs Industry Average Movement	6.3%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.8%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: G5B's share price has been volatile over the past 3 months.

Volatilità nel tempo: G5B's weekly volatility has increased from 12% to 17% over the past year.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2011	457	Ted Love	www.gbt.com

Global Blood Therapeutics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Global Blood Therapeutics con la sua capitalizzazione di mercato?
G5B statistiche fondamentali
Capitalizzazione di mercato	€4.69b
Guadagni(TTM)	-€327.07m
Ricavi(TTM)	€238.22m

19.7x

Rapporto P/S

-14.3x

Rapporto P/E

G5B è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
G5B Conto economico (TTM)
Ricavi	US$234.86m
Costo del fatturato	US$4.45m
Profitto lordo	US$230.41m
Altre spese	US$552.87m
Guadagni	-US$322.46m

Ultimi guadagni dichiarati

Jun 30, 2022

Prossima data di guadagno

n/a

Utile per azione (EPS)	-4.78
Margine lordo	98.10%
Margine di profitto netto	-137.30%
Rapporto debito/patrimonio netto	491.7%

Come si è comportato G5B nel lungo periodo?

Vedi performance storica e confronto

This company listing is no longer active

G5B Panoramica delle azioni

Premi

Analisi del rischio

Global Blood Therapeutics, Inc. Concorrenti

XTRA:BIO3

€1.3b

XTRA:FYB

€937.6m

XTRA:MOR

€2.5b

XTRA:HPHA

€112.3m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from NASDAQ Composite Index

Pfizer Inc. (NYSE:PFE) completed the acquisition of Global Blood Therapeutics, Inc. (NasdaqGS:GBT) from a group of shareholders.

CFO & Principal Accounting Officer recently sold €1.9m worth of stock

Executive Vice President of Operations recently sold €310k worth of stock

Pfizer Inc. (NYSE:PFE) entered into a definitive agreement to acquire Global Blood Therapeutics, Inc. (NasdaqGS:GBT) for $5 billion.

Pfizer Inc. (NYSE:PFE) entered into a definitive agreement to acquire Global Blood Therapeutics, Inc. (NasdaqGS:GBT) for $5 billion.

Recent updates

Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from NASDAQ Composite Index

Pfizer Inc. (NYSE:PFE) completed the acquisition of Global Blood Therapeutics, Inc. (NasdaqGS:GBT) from a group of shareholders.

CFO & Principal Accounting Officer recently sold €1.9m worth of stock

Executive Vice President of Operations recently sold €310k worth of stock

Pfizer Inc. (NYSE:PFE) entered into a definitive agreement to acquire Global Blood Therapeutics, Inc. (NasdaqGS:GBT) for $5 billion.

Pfizer Inc. (NYSE:PFE) entered into a definitive agreement to acquire Global Blood Therapeutics, Inc. (NasdaqGS:GBT) for $5 billion.

Second quarter 2022 earnings released: US$1.26 loss per share (vs US$1.12 loss in 2Q 2021)

Pfizer Reportedly in Advanced Talks to Buy Global Blood Therapeutics for $5 Billion

Global Blood Therapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

MHRA Grants Marketing Authorization for Global Blood Therapeutics, Inc.'s Oxbryta (Voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older

Global Blood Therapeutics, Inc. Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease

Global Blood Therapeutics, Inc. Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta (Voxelotor) in Sickle Cell Disease

Global Blood Therapeutics, Inc.'s Inclacumab and GBT601 Receive U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for the Treatment of Sickle Cell Disease

First quarter 2022 earnings released: US$1.26 loss per share (vs US$1.21 loss in 1Q 2021)

No longer forecast to breakeven

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Global Blood Therapeutics, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Global Blood Therapeutics, Inc. Announces Positive Early Access to Medicines Scheme Scientific Opinion

Global Blood Therapeutics, Inc. announces Oxbryta® (voxelotor) tablets for oral suspension

Forecast to breakeven in 2024

Global Blood Therapeutics, Inc. Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12 Years and Older

Global Blood Therapeutics, Inc. Presents Positive Results from Phase 1 Study of Gbt021601 in Patients with Sickle Cell Disease and Healthy Volunteers At ASH Annual Meeting and Exposition

GBT Presents Positive New Data on Oxbryta® (voxelotor) in Patients with Sickle Cell Disease at ASH Annual Meeting and Exposition

Third quarter 2021 earnings released: US$1.13 loss per share (vs US$0.97 loss in 3Q 2020)

Independent Director recently sold €123k worth of stock

Global Blood Therapeutics, Inc. Announces the U.S. Food and Drug Administration Accepts for Priority Review Supplemental New Drug Application for Oxbryta (Voxelotor)

Second quarter 2021 earnings released: US$1.12 loss per share (vs US$0.86 loss in 2Q 2020)

Global Blood Therapeutics, Inc. Provides Regulatory and Pipeline Updates in Sickle Cell Disease

Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from Russell Midcap Growth Index

Global Blood Therapeutics, Inc. Announces Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine Designation in the UK

Global Blood Therapeutics, Inc. Announces New Data from the Phase 2a HOPE-KIDS 1 Study

Global Blood Therapeutics, Inc. Provides Revenue Guidance for the Second Quarter of 2021

First quarter 2021 earnings released: US$1.21 loss per share (vs US$1.20 loss in 1Q 2020)

Global Blood Therapeutics, Inc. Appoints Alexis A. Thompson to the Board as A Class I Director

New 90-day low: €33.02

Revenue beats expectations

Global Blood Therapeutics, Inc. to Report Q4, 2020 Results on Feb 24, 2021

New 90-day high: €42.24

Global Blood Therapeutics, Inc. Expands Access Protocol for Oxbryta in Pediatric Patients with Sickle Cell Disease

European Medicines Agency Accepts Global Blood Therapeutics, Inc.’s Marketing Authorization Application for Oxbryta (Voxelotor) for the Treatment of Hemolytic Anemia in Sickle Cell Disease

GBT Presents New Data on the Long-Term and Real-World Use of Oxbryta® (voxelotor) Tablets in Patients with Sickle Cell Disease at 62nd ASH Annual Meeting and Exposition

Global Blood Therapeutics, Inc. Presents Data on New Sickle Cell Disease Pipeline Therapies with Best-in-Class Potential – Inclacumab and GBT021601

Global Blood Therapeutics, Inc. Initiates Early Access Program for Voxelotor

New 90-day low: €31.78

Revenue misses expectations

Global Blood Therapeutics, Inc. Announces Upcoming Virtual Data Presentations at 62nd American Society of Hematology (ASH) Annual Meeting & Exposition

Global Blood Therapeutics, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low - €49.58

New 90-day low - €49.81

Global Blood Therapeutics, Inc. to Report Q2, 2020 Results on Aug 05, 2020

Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from Russell 2000 Dynamic Index

Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from Russell 2000 Index

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Global Blood Therapeutics, Inc. Riepilogo dei fondamenti

19.7x

-14.3x